Search

Displaying results 5491 - 5500 of 10000 in total
  1. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

  2. Drug

    Girentuximab

    go.drugbank.com/drugs/DB05304
    Investigational

    Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

  3. Drug

    Dihydroxyacetone phosphate

    go.drugbank.com/drugs/DB04326
    Investigational

    Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.

  4. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.

  5. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  6. Drug

    AZD8630

    go.drugbank.com/drugs/DB19397
    Investigational

    AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics

  7. Drug

    Cloridarol

    go.drugbank.com/drugs/DB13291
    Experimental

    Cloridarol is an experimental medication in the treatment of heart disease, which acts through vasodilation. It was studied for the treatment of coronary insufficiency in Italy in the 1970s [A176222].

  8. Drug

    9,10-Deepithio-9,10-Didehydroacanthifolicin

    go.drugbank.com/drugs/DB02169
    Experimental

    A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)

  9. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].

  10. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies … Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species.

    Synonyms: 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate